Recombinant herpes simplex virus type 1 (rHSV)-assisted recombinant adeno-associated virus (rAAV) vector production provides a highly efficient and scalable method for manufacture of clinical grade rAAV vectors. Here, we present an rHSV co-infection system for rAAV production, which uses two ICP27-deficient rHSV constructs, one bearing the rep2 and cap (1, 2 or 9) genes of rAAV, and the second bearing an AAV2 ITR-gene of interest (GOI) cassette. The optimum rAAV production parameters were defined by producing rAAV2/GFP in HEK293 cells, yielding greater than 9000 infectious particles per cell with a 14:1 DNase resistance particle to infectious particle (DRP/ip) ratio. The optimized co-infection parameters were then used to generate large-scale stocks of rAAV1/AAT, which encode the human a-1-antitrypsin (hAAT) protein, and purified by column chromatography. The purified vector was extensively characterized by rAAV-and rHSV-specific assays and compared to transfection-made vector for in vivo efficacy in mice through intramuscular injection. The co-infection method was also used to produce rAAV9/AAT for comparison to rAAV1/AAT in vivo. Intramuscular administration of 1 Â 10 11 DRP per animal of rHSV-produced rAAV1/AAT and rAAV9/ AAT resulted in hAAT protein expression of 5.4 Â 10 4 and 9.4 Â 10 5 ng ml À1 serum respectively, the latter being clinically relevant.
Introduction
The use of recombinant adeno-associated virus (rAAV) as a gene delivery vehicle has been pursued for over two decades and has a number of advantages as a gene transfer vector. [1] [2] [3] AAV is a replication-defective parvovirus whose natural infections are characterized by a lack of pathogenic consequences and can result in site-specific, chromosomal integration of the viral genome. [4] [5] [6] Recombinant AAV vectors are attractive for gene delivery because they transduce a broad spectrum of proliferating and quiescent cell types, accommodate tissue-specific promoters, and elicit diminished immune response relative to other viral vectors. Recent application of rAAV vectors in human clinical trials for hemophilia B, 7, 8 Parkinson's disease, 9 late infantile neuronal ceroid lipofuscinosis, 10 limb-girdle muscular dystrophy, 11 cystic fibrosis, 12 rheumatoid arthritis 13 and a-1-antitrypsin deficiency 14 underscore the requirement for scalable rAAV vector production and purification protocols for human gene therapy applications.
Recombinant viral vectors of AAV are generated by encapsidating a therapeutic gene of interest (GOI) in lieu of the wild-type virus rep and cap genes. rAAV production requires the intracellular delivery of the relevant proviral DNA construct, the rep and cap genes of the serotype(s) of interest and helper virus functions. 15 The proviral construct consists of the cDNA expression cassette flanked by the AAV inverted terminal repeats (ITRs), which are the minimal cis-acting sequences required to direct DNA replication and packaging. 1, 16 The rep gene codes for four Rep proteins (78, 68, 52 and 40) that function in trans to replicate the rAAV genome, resolve replicative intermediates and package single-stranded rAAV genomes, while the cap gene encodes for the three structural proteins (VP1, VP2 and VP3) that comprise the virus capsid. [17] [18] [19] Two helper viruses have been shown to efficiently compliment rAAV replication in vitro, herpes simplex virus (HSV) and adenovirus. In the case of adenovirus, the helper functions have been defined as the E1a, E1b, E2a, E4orf6 and virusassociated RNA I genes, which together establish an intracellular environment that permits maximum rAAV production. [20] [21] [22] [23] Numerous approaches to rAAV vector manufacture have been pursued, including stable proviral cell lines, stable packaging cell lines that express the rep and cap genes of AAV, and multi-plasmid transient transfection systems. [24] [25] [26] Multi-plasmid transient transfection remains the most widely used method for rAAV production, where one plasmid bears the GOI flanked by the AAV ITR's, while a second plasmid bears the rep and cap genes of AAV. Triple transfection systems use a third plasmid with the adenovirus helper function genes but can be simplified to a co-transfection by inclusion of the helper genes in the rep-cap plasmid. 24, 27 Unfortunately, most transfection-based methods are difficult to adapt to large-scale production and result in low specific yields of infectious particles (ip) and DNase resistance particles (DRP), and often result in high DRP/ip ratios (50-100). 27, 28 More recently, novel approaches using alternate helper viruses and non-mammalian cells have been investigated. In lieu of adenovirus infection or transfection of plasmid-expressed adenovirus helper genes, recombinant HSV (rHSV) can also support rAAV replication. 29 The minimum HSV helper genes are the HSV helicaseprimase complex (U L 5, U L 8, U L 52), the HSV DNA polymerase and the HSV DNA-binding protein (U L 29) genes. 30 These genes promote replication and packaging at approximately 1-2% of the level seen with wild-type HSV (wtHSV) or adenovirus. Production systems using rHSV helper functions (infection, plasmid transfection or amplicons) have been successful in generating specific rAAV yields comparable to transfection, or better. [31] [32] [33] [34] [35] [36] [37] [38] rAAV production using the insect baculovirus Autographa californica nuclear polyhedrosis has also been investigated in HEK293 cells and Spodoptera frugiperda (Sf9) cells. [39] [40] [41] [42] Unfortunately, a stable rAAV complementation system that produces specific viral yields comparable to wild-type AAV (wtAAV) (approximately 1.4 Â 10 4 ip per cell) have not been reported yet. 29 This manuscript describes an rAAV production protocol that exploits the simultaneous co-infection of mammalian cells with two replication-deficient rHSV-1 viral vectors for high-titer rAAV production, one bearing the AAV rep and cap genes and the second containing the GOI flanked by the AAV2 ITRs. In contrast to previously published rHSV-assisted rAAV vector manufacturing systems, the rHSV co-infection method reported here generates very high specific yields of infectious virus, results in a very low DRP/ip ratio, can be successfully executed on several cell lines, and can produce multiple serotypes with high specific yields. Optimized yields of rAAV serotypes 1 and 2 using either marker or therapeutic transgenes were in excess of 5 Â 10 4 DRP per cell in HEK293 cells, while maintaining a low particle to infectivity ratio (DRP/ip). rAAV1 vector stocks carrying the human a-1-antitrypsin gene were generated by rHSV co-infection, characterized for potency and purity, and compared in vivo to transfection-produced rAAV1 and coinfection-produced rAAV9 vectors in mice.
Results

Optimization and characterization of rAAV yield
The rHSV co-infection procedure described here separates the cis-and trans-acting AAV elements to reduce replication competent AAV generation, and to permit flexibility in modulating the ratio of the rep and cap functionalities relative to the ITR-transgene cassette by varying the multiplicities of infection (MOI) of the two rHSV constructs (Figure 1 ). This split helper approach is similar to transfection-based systems previously reported. 23, 43, 44 The ICP27-deficient rHSV vectors (irHSV) limit the generation of replication-competent HSV during the rAAV production process and were propagated on the ICP27-complimenting V27 cell line in Nunc cell factories, as previously described. 45, 46 HEK293 cells were simultaneously co-infected with rHSV-rep2/cap2 and rHSV-GFP ( Figure 2 ) at various MOI ratios and specific yields of infectious rAAV2/GFP vector were quantified by a green cell assay. The rHSV co-infection ratio was empirically determined by varying the rHSV-GFP MOI at a constant rHSV-rep2/cap2 MOI of four (data not shown), then optimizing the rHSV-rep2/cap2 MOI at a constant rHSV-GFP MOI of two. The optimum rHSV coinfection ratio of rHSV-rep2/cap2 to rHSV-GFP was determined to be 12:2. The specific yield (ip per cell) of rAAV2 was insensitive to the rHSV-GFP MOI between two and four, and declined at lower or higher MOI (data not shown). The specific yield of rAAV2 was sensitive to the rHSV-rep2/cap2 MOI as indicated in Figure 2 and showed an optimum at an MOI of 12. rAAV harvest timing was examined between 22 and 68 hpi with peak production of infectious vector at 52 hpi (±4 hpi). Figure  2 indicates that a rAAV2/GFP productivity of 6400 ± 965 ip per cell was achieved at the optimum MOI ratio of 12:2 on HEK293 cells. Studies conducted with an hour or more delay in infection of either rHSV vector resulted in significant declines in specific yields of rAAV2 (data not shown), indicating that simultaneous co-infection was the optimum infection method for producing rAAV.
The optimized co-infection production protocol was applied to HEK293 cells at small scale (1 Â 10 7 cells) with rHSV-rep2/cap2 and either rHSV-GFP or a therapeutic rHSV-GOI construct for production of rAAV2. Crude viral stocks were generated as described in Materials and methods and were characterized for rAAV2 infectivity using an infectious center assay or the green cell assay. DRPs were enumerated using real-time quantitative PCR (qPCR), and total intact capsids (full and empty) using the A20 enzyme-linked immunosorbent assay (ELISA). The results are shown in Table 1 . For both the GFP (green fluorescent protein) and therapeutic transgene cassettes, the specific yield of ip was close to that observed for wtAAV with wtAdenovirus co-infection on HeLa cells. 29 Moreover, the particle to infectivity ratio was low at approximately 10:1.
The optimum input ratio of rHSV vector produces the correct Rep ratio
Previous study had shown that the proper modulation of Rep protein expression is critical for rAAV production. 23, 27, 47, 48 To examine what effect the rHSV MOI ratio of 12:2 had on the expression of Rep proteins, crude lysates were isolated as a function of time post-rHSV coinfection and subjected to western analysis ( Figure 3) . The relative expression of Rep78 to Rep52 was approximately 1:10 at all time points. This result is similar to the Rep protein ratios seen in cells infected with wtAAV and Ad. 49, 50 Rep52 expression was dominant for all points preceding 72 hpi, suggesting that Rep protein toxicity might have been minimized due to the relatively low level of large Rep (78, 68) protein expression from the HSV backbone until late in the rAAV production process. The levels of the spliced Rep proteins, Rep68 and Rep40, were low at all time points as previously reported. 49, 50 HSV co-infection production of rAAV2/GFP in other cell lines
Once the rHSV co-infection parameters (MOI ratio, cell density, harvest timing) were established for HEK293 cells, the method was applied to other cell types to explore the robustness of the production system. Table 2 lists several cell types used to test the rHSV co-infection Efficient rHSV-based production of rAAV serotypes W Kang et al method for rAAV production. Cells were seeded into replicate flasks and infected 20-24 h later. Cell populations were estimated by harvesting and enumerating a T75 flask for viable cells for each cell type just before infection. The cell lines were selected based on several criteria, including HSV infection susceptibility, literature precedent of rAAV production and biologic safety level considerations. Cell lines were screened for rAAV productivity by co-infecting with rHSV-rep2/cap2 and rHSV-GFP and the infected cells were harvested at 52 ± 4 hpi. Productivity was assessed by green cell assay. The rAAV2 yields obtained are summarized in Table 2 . In general, kidney-derived cell lines and an epithelial cell line (HT1080) produced the highest specific rAAV yields (X1000 ip per cell). In contrast, the specific yields from lung, muscle and retinal cell lines had low-to-moderate 
KpnI Figure 1 The relevant genetic sequences for recombinant adeno-associated virus (rAAV) production using recombinant herpes simplex virus (rHSV) helper vectors. (a) The wild-type AAV2 genome (b) The ICP27 negative HSV vector showing a blowup of the ICP27 deletion (between BamHI and StuI, reference 45), the rep2/capX cassette insertion into the thymidine kinase (TK) gene of one ICP27-deleted rHSV vector, where capX is the capsid gene from AAV1, 2 or 9, and the AAV2 ITR-GOI cassette insertion into the TK gene of a second ICP27-deleted rHSV vector, where the gene of interest (GOI) can be any therapeutic or marker gene such as green fluorescent protein (GFP) or human a-1-antitrypsin (hAAT).
Efficient rHSV-based production of rAAV serotypes W Kang et al rAAV-specific yields (40-600 ip per cell). Two cell lines, HeLa (cervical carcinoma) and GeLu (gerbil lung) produced almost no rAAV. The cell lines that produced the most rAAV were human (HEK293), hamster (BHK 21) and monkey (Vero and Cos-7) cell lines. These data confirm that human herpes virus functions as a helper for rAAV production in cell lines from a variety of species, in contrast to adenovirus, which may be restricted to human cell lines. 51 rHSV vector stability and rAAV production
The stability of rAAV helper constructs during serial passage can impact the utility of helper vector systems for large-scale manufacturing. The stability of the rHSV-rep2/cap1 and rHSV-AAT vectors was examined by serial expansion on V27 cells in T75 flasks and subsequent rAAV production. The rHSV-rep2/cap1 construct was stable for at least 13 passages ( Figure 4a ) and the rHSV-AAT construct was stable for at least 8 passages ( Figure 4b ) with no statistically significant change in their ability to produce rAAV. This level of rHSV-AAT stability is sufficient to produce enough rHSV to infect a total of 2.7 Â 10 13 liters of cells for rAAV production, and suggests that the rHSV system can be modified easily for large-scale production.
Production, purification and characterization of rAAV vector stocks
Recombinant AAV1 vectors produced by rHSV coinfection were purified by a three-column chromatography system. rAAV1/AAT vector production was carried out at a scale of 5 Â 10 9 cells in Nunc cell factories. Cells were harvested, lysed, clarified, concentrated and buffer exchanged before column chromatography. rAAV1/AAT column chromatography purification runs were executed at a 1 Â 10 9 cell load (first column). rAAV9/AAT was produced at a scale of 2 Â 10 9 cells in Nunc cell factories and purified by double iodixanol gradient centrifugation.
Purified rAAV1/AAT was characterized by several assays (Table 3) , including assays for potency (infectivity) and physical titer (DRP), both of which are required for clinical product release and dosing. An infectious center assay with a transgene-specific probe was used for infectivity determination and qPCR or dot blot was used to assay DRP (see Materials and methods). Purified vector stocks produced by rHSV co-infection were also assayed for residual process contaminants, including HSV protein (ELISA), HSV DNA (qPCR), infectious rHSV (plaque-forming unit assay) and Benzonase (Table  3) . Protein purity was characterized by SDS gel electrophoresis followed by silver staining.
Recombinant AAV1 purified by three-column chromatography yielded highly pure rAAV. Only the VP1, VP2 and VP3 proteins were visible by sliver staining ( Figure 5 ). The DRP/ip ratios of rAAV1/AAT stocks purified by three-column chromatography (Table 3) were higher than the crude rAAV2 stocks tested (Table 1) ; however this most likely reflects the lower in vitro infectivity of rAAV1 on human cell lines relative to rAAV2. The DRP/ip ratio of purified transfection-made vector was 595 while that of rHSV co-infection-made vector was 117, a 5.1-fold difference. The residual HSV Figure 3 Rep protein expression as a function of time postrecombinant herpes simplex virus (rHSV) co-infection. T75 flasks were co-infected with rHSV-rep2/cap2 and rHSV-GFP at a multiplicity of infection ratio of 12:2 and cells were harvested at the indicated intervals. Whole cell lysates were then immunoblotted with a Rep-specific antibody as described in Materials and methods.
Efficient rHSV-based production of rAAV serotypes W Kang et al DNA concentration of 3.3 ng ml À1 corresponded to about a 2400-fold clearance relative to the infection step.
In vivo characterization of human a-1 antitrypsin expression from rAAV vectors
Recombinant AAV1/AAT stocks produced by rHSV coinfection and transient two-plasmid transfection were purified by three-column chromatography, characterized by AAV-and HSV-specific assays (Table 3) , and administered to mice to evaluate expression of human AAT. C57BL/6 mice were intramuscularly injected with 1 Â 10 10 or 1 Â 10 11 DRP of rHSV-produced or transfectionproduced rAAV1/AAT, and serum hAAT expression was measured using a human AAT-specific ELISA. The rHSVderived vector resulted in an average of a 5.4-fold (1 Â 10 10 DRP dose) or 5.2-fold (1 Â 10 11 DRP dose) increase of hAAT expression ( Figure 6 ) relative to the transfectionproduced rAAV1/AAT. This suggests that the lower DRP/ip ratio of the HSV-derived rAAV1/AAT vector was reflected in the higher hAAT serum expression.
The biological activity of rAAV9/AAT vector produced by rHSV co-infection was also evaluated in vivo with rAAV1/AAT administration for comparison. C57BL/6 mice were intramuscularly (rAAV1 and rAAV9) or intrapleurally (rAAV9) injected with 1 Â 10 11 DRP per animal and serum hAAT expression quantified as before ( Figure 7) . Expression of hAAT from rAAV9/AAT resulted in a 14-to 17-fold increase in expression, independent of delivery method, relative to hAAT serum levels expressed from rAAV1/AAT delivered intramuscularly.
Discussion
The use of rAAV in gene delivery protocols is currently underway in both preclinical animal studies and human clinical trials for the treatment of a variety of diseases. The benefits of using rAAV for gene therapy relative to other viral vectors include long-term gene expression, transduction of mitotic and post-mitotic cells, the inability to autonomously replicate without a helper Abbreviations: GFP, green fluorescent protein; MOI, multiplicities of infection; ip, infectious particle; rAAV, recombinant adeno-associated virus. MOI ratio was 12:2 (rHSV-rep2/cap2:rHSV-GFP) and rAAV was harvested at 52±4 hpi for all experiments.
rHSV-rep2/cap1 passage no. from plaque rAAV1/AAT production (DRP/cell) Efficient rHSV-based production of rAAV serotypes W Kang et al virus (or functions) and the lack of pathogenic consequences from (natural) infections. In the past, the obstacles to use rAAV have included the limited transgene packaging capacity of about 4.5 kb, low specific yields (relative to wtAAV and adenovirus) and limited scalability of production methods such as transfection. 23, 27 Alternative approaches such as stable cell-line generation for production of rAAV have been successful; however, cloning and selection, stability and recombination event generation of replication competent virus are all potential obstacles. 24, 26 Insect cell production of rAAV provides a highly promising, scalable rAAV manufacturing system with specific yields (DRP per cell) similar to those reported here; however, construct stability during expansion and rAAV2 production with very high (41000) DRP/ip ratios suggest that further refinement is needed. 39, 41, 42 This report details an alternative rAAV production method, which is flexible, scalable and generates high rAAV yields. The rHSV vectors used here are readily propagated to high titer on the V27 permissive cell line in both tissue culture flasks and bioreactors. 46 The use of separate rHSV vectors to deliver the rep-cap and ITR-GOI constructs affords a flexible method for modulating the cis-and trans-acting complementation elements for AAV production, similar to previous transfection reports. 23, 44, 52 Here, we found the input MOI ratio of the rHSV-rep2/cap2 and rHSV-GFP vectors used for the production showed an optimum at 12:2. Co-infection of multiple mammalian cell lines with irHSV resulted in high specific yields of infectious rAAV vector (Table 2) , while very low DRP/ip ratios (8) (9) (10) (11) (12) (13) (14) were generated on HEK293 cells during rAAV2 production (Table 1) . These yield and DRP/ip ratio data compare favorably to methods previously reported. 23, 27, [37] [38] [39] 41, 42 Indeed, the amount of virus generated (ip per cell) is comparable to wtAAV yields when wild-type adenovirus or wtHSV is used as a helper virus, demonstrating that the rHSV coinfection complementation system is highly efficient. 29 Furthermore, the low DRP/ip ratios suggest that lower patient dosing (total particles) of rHSV-produced rAAV (with respect to transfection production) could achieve the same level of therapeutic expression. Indeed, this appeared to be the case in the murine administration experiment (Figure 6 ), in which rHSV-produced rAAV1/ AAT resulted in about a five-fold greater expression of AAT relative to transfection-produced vector when administered at the same dose (DRP per mouse). The DRP/ip ratio difference and resulting AAT expression difference appear to be directly related to the production method, as the transfection and rHSV-produced rAAV1/ AAT were purified by the same three-column chromatography system. Finally, HSV helper functions bypass the host range restriction for AAV production, which limit Adenovirus helper-assisted rAAV production to human cell lines, as adenoviruses with alternate species tropism have been poorly characterized. In contrast, HSV is capable of replicating and providing helper functions in cells from a variety of mammalian species. 51 The co-infection system was successful in producing rAAV serotypes 1, 2 and 9, with rAAV9/AAT resulting in clinically relevant a-1-antitrypsin protein expression in serum when administered to C57BL/6 mice. All vectors Limit of detection. The lowest value that could be detected but not quantified (that is, a sample that amplified by qPCR whose C t was slightly higher than the most dilute standard's C t ). Efficient rHSV-based production of rAAV serotypes W Kang et al produced consisted of the AAV2 ITR sequences flanking a GOI packaged into AAV1, 2 or 9 capsids. Thus the rHSV co-infection system was successful at producing combinations of three different pseudo-typed vectors packaging three different transgenes, demonstrating the flexibility and applicability of the system. Serotypes 1 and 9 were both evaluated in vivo and shown to be biologically active, while serotype 2 has previously been used in animal studies and proven biologically active with the therapeutic gene evaluated here. 53 This is in contrast to other helper systems, which have required genetic manipulation to ensure serotypes other than rAAV2 remain infectious on mammalian cells. 42 The murine administration experiment (Figure 7) revealed that equivalent dosing (1 Â 10 11 DRP per animal) of rAAV9/AAT resulted in substantially higher serum expression of hAAT relative to rAAV1/AAT. rAAV9/ AAT delivered either intramuscularly or intrapleurally to C57BL/6 mice expressed 17-or 14-fold higher hAAT, respectively, in serum by 2 months post-injection relative to the same dose of rAAV1/AAT. The administration of rAAV9/AAT produced by irHSV co-infection appears extremely promising in generating therapeutically relevant hAAT expression in animals.
Several rHSV helper-assisted AAV vector manufacturing systems have previously been reported, including Conway et al., Toublanc et al., Booth et al. and Wustner et al. 31, 34, 37, 38 The rHSV co-infection method differs from Conway et al. in that all rAAV genetic elements are delivered through rHSV infection, a proviral cell line is not required, and the 9400 ip per cell of rAAV obtained here (Table 1) is a substantial improvement relative to their results (480 eu per cell). The rHSV co-infection system of Booth et al. bears the closest resemblance to that described here; however, direct comparison is still difficult, given production parameter and cell line differences. Booth et al. explored rAAV2/GFP production using irHSV co-infection of BHK cells and reported 155 000 capsid per cell at a scale of 1 Â 10 7 cells, with a capsid to expressing unit (eu) ratio of 3875. 37 Our rAAV2 productions at the same scale in HEK293 cells (Table 1) resulted in 1.6 Â 10 6 or 1.2 Â 10 6 capsid per cell with capsid to ip ratios of 170 and 150 for the GFP and therapeutic transgene productions, respectively. Furthermore, we were able to produce 6900 ip per cell (Table 2) with rHSV co-infection of BHK cells, compared to 40 eu per cell for Booth et al. Toublanc et al. reported that wtHSV was superior to irHSV-supplied helper functions during rAAV production in an HeLa-based packaging cell line which harbored the rep and cap genes of AAV2 stably integrated into the chromosome. 38 We also observed a low specific yield of rAAV2 when HeLa cells (Table 2) were co-infected with irHSV vectors, confirming their results. One possible explanation for these data is that ICP27-deficient HSV infection would be expected to induce apoptosis in human cell lines. [54] [55] [56] Perhaps the adenovirus-derived E1 region in HEK293 cells is capable of suppressing irHSV-induced apoptosis, whereas the HPV-derived E6 expression in HeLa is not. 57 Previously, large-scale production of clinical-grade rAAV vector has been hampered by the use of inefficient manufacturing techniques such as transfection. The rHSV co-infection method for rAAV production reported here circumvented transfection and genetically engineered cell lines, and permitted the production of multiple pseudo-typed vectors comprised of several serotype/GOI combinations. The high specific yield of rAAV and low DRP/ip ratio obtained with the co-infection method make it highly attractive for largescale vector production and purification. Sustained, clinically relevant human a-1-antitrypsin expression was measured in mice after injection with rAAV9/AAT produced by rHSV. Further research with the rHSV coinfection system in the areas of alternate serotype cloning and production, removal of animal-derived components (') DRP of rHSV co-infection derived rAAV1/AAT was injected and production of human AAT was measured in serum by enzyme-linked immunosorbent assay (ELISA) at the indicated intervals. Mock administration was less than the limit of detection of the human a-1-antitrypsin (hAAT) ELISA. Dose administration was determined by dot blot; error bars indicate standard deviation and n ¼ 6 for each injection group. Figure 7 Biological activity of recombinant herpes simplex virus (rHSV)-produced rAAV1/AAT and rAAV9/AAT vectors. rAAV1/ AAT was administered intramuscularly (&) and rAAV9/AAT was administered either intramuscularly (') or intrapleurally ( ) into C57BL/6 mice. 1 Â 10 11 DNase resistance particles was injected as indicated and human a-1-antitrypsin (hAAT) was measured at one and two months post-injection. Error bars indicate standard deviation and n ¼ 3 (rAAV1/AAT IM), n ¼ 4 (rAAV9/AAT IP) or n ¼ 5 (rAAV9/AAT IM).
Efficient rHSV-based production of rAAV serotypes W Kang et al from the upstream process (for example, fetal bovine serum, trypsin) and adaptation to a suspension format to facilitate bioreactor scaling are underway in our laboratories.
Materials and methods
Cell lines and viruses
Mammalian cell lines were maintained in Dulbecco's modified Eagle's medium (Hyclone, South Logan, UT, USA) containing 10% (v/v) fetal bovine serum (Hyclone) unless otherwise noted. Cell culture and virus propagation were performed at 37 1C, 5% CO 2 for the indicated intervals. HEK293 cells were obtained from the University of Florida Powell Gene Therapy Center, all other cell lines were procured from ATCC.
rHSV-1 vector construction and production
The ICP27-deleted rHSV-rep2/cap2 vector was originally derived from the wtHSV KOS isolate (formerly denoted d27.1-rc), and has previously been described. 31 Additional rHSV-rep2/capX constructs were generated by homologous recombination of an AAV rep2 and capX gene cassette into the tk locus of the rHSV-1, ICP27-deleted d27.1 vector. The AAV rep and cap genes are under control of their native promoters (p5, p19 and p40) in the rHSV-rep2/capX vectors. The rHSV-GFP vector was constructed by homologous recombination of a cytomegalovirus promoter-driven hGFP-neomycin resistance gene cassette, flanked by the AAV2 ITRs, into the tk locus of the d27.1 vector. 58 Similarly, the rHSV-AAT vector was constructed by homologous recombination of a CBA promoter-driven hAAT-neomycin resistance gene cassette flanked by the AAV2 ITRs into the same locus.
The rHSV vectors were propagated on the ICP27-complementing cell line V27. V27 is an ICP27-expressing Vero cell line derivative, which harbors approximately one copy of the ICP27 gene per haploid genome equivalent. 45 Infection steps were carried out in the absence of serum. Vector stocks were propagated in T225 flasks and Nunc cell factories as previously described. 46 
HSV-specific assays
Recombinant HSV vector stocks were quantified by a modified plaque assay on V27 cells (1.5 Â 10 6 cells per well seeded) in six-well plates as previously described. 46 Viral plaques were scored as dark brown spots with a limit of quantification (LOQ) of 20 PFU ml Herpes simplex virus protein in rAAV stocks was assayed by ELISA. Whatman 96-well polystyrene plates were coated with a polyclonal rabbit anti-HSV antibody (Dako Denmark A/S, Glostrup, Denmark, catalog no. B-0114) at 5 mg ml À1 by incubating at 37 1C for 2 h and blocked with 1X phosphate-buffered saline containing 0.05% (v/v) Tween 20 and 1% (w/v) bovine serum albumin at 37 1C for 1 h. HSV protein standards and unknowns were serially diluted in blocking solution, applied to the 96-well plates (100 ml per well), and incubated for 12-18 h at 4 1C. Captured protein was hybridized with a polyclonal anti-HSV, HRP-conjugated antibody (Dako, catalog no. P0175) diluted 1:500 in blocking solution, incubated at 37 1C for 2 h, and visualized with SuperSignal ELISA Femto Maximum Sensitivity Substrate (Pierce Biotechnology, Rockford, IL, USA, catalog no. 37075). The LOQ was 1 ng ml À1 .
rAAV-specific assays
Infectious rAAV/GFP particles were quantified by a modified single-cell fluorescence assay. 28 Ninety-six well plates were seeded with C12 cells (1.2 Â 10 4 cells per well) and infected (200 ml) 24 h later with 10-fold serial dilutions of crude rAAV/GFP stocks containing Ad5 (MOI of 10). 26, 59 Infectious rAAV/GFP particles were scored as green fluorescing cells at 50-65 hpi. rAAV2/ GFP stocks were assayed in quadruplicate and ip titers were averaged.
Infectivity of therapeutic transgene rAAV constructs was assayed by an infectious center assay. C12 cells were seeded and infected as above, and harvested at 44-48 hpi by incubating wells with 1X phosphate-buffered saline containing 5 mM EDTA. Harvested cells were transferred to Biodyne B membrane (Pall Life Sciences Biosciences, Ann Arbor, MI, USA, catalog no. 60209), alkaline lysed (0.5 M NaOH/1.5 M NaCl), neutralized (0.5 M Tris-HCl, pH 7.5/1.5 M NaCl), and the liberated DNA crosslinked to the membrane by microwave. Crosslinked DNA was hybridized to gene-specific probes and detected using the North2South Chemiluminescent Hybridization and Detection Kit (Pierce) reagents following the manufacturer's instructions. Infection-replication events were scored as luminescent, hybridized DNA spots. The LOQ was about 2000 ip per ml.
Recombinant AAV DRP were assayed in clarified or purified lysate (10 ml) by incubating in the presence of 50 U ml
À1
DNAse I (Promega Biosciences, Inc., Madison, WI, USA) at 37 1C for 1 h in a 1 ml reaction. DNAse-treated samples were digested with 25 mg ml
Proteinase K (Invitrogen, Grand Island, NY, USA) at 50 1C for 1 h. DRP were enumerated by qPCR using forward (5 0 -AGCAATAGCATCACAAATTTCACAA-3 0 ) and reverse (5 0 -CCAGACATGATAAGATACATTGATG AGTT-3 0 ) primers and probe ( 5À6ÀFAM AGCATTTTTTTC ACTGCATTCTAGTTGTGGTTTGTC TAMRA3À ) to the SV-40 polyA sequence in the ITR-flanked gene cassette (ABI). Dot-blot titers for animal dosing were determined by the University of Florida Powell Gene Therapy Center Vector Core by dot blot, using a CBA-promoter-specific probe and 32 P labeling as previously described. 28 Efficient rHSV-based production of rAAV serotypes W Kang et al
Process-specific assays
Purity of large-scale rAAV stocks was verified by silver staining using the NativePAGE Novex Bis-Tris Gel System (Invitrogen). Purified rAAV samples were prepared as per the manufacturer's instructions, denatured at 95 1C for 5 min, and electrophoretically separated on 4-12% Bis-Tris pre-cast gels. Protein was visualized using the SilverXpress Silver Staining Kit (Invitrogen, catalog no. LC6100) as per the manufacturer's instructions. Residual Benzonase was quantified using the Benzonase ELISA II (EMD Chemicals, Inc., Gibbstown, NJ, USA, catalog no. 1.01681.0002) assay per manufacturer's instructions. The LOQ was 1 ng ml À1 .
Western analysis for Rep expression in rHSV co-infected cells T75 flasks were seeded with 1 Â 10 7 HEK293 cells, co-infected 24 h after seeding with rHSV-rep2/cap2 (MOI 12) and rHSV-GFP (MOI 2), and harvested at the indicated intervals. Cells were collected by centrifugation (5 min, 4 1C, 280 g) and crude lysate generated by resuspending in RIPA buffer comprised of 1X phosphatebuffered saline (100 ml) containing 1% (v/v) NP-40, 0.25% (w/v) DOC, 0.1% (w/v) SDS, and 1 mg ml À1 each of the protease inhibitors aprotinin, leupeptin and pepstatin and 1 mM phenyl methyl sulfonyl fluoride. Protein in clarified lysate was denatured by incubation at 100 1C for 10 min in the presence of 2.5% (v/v) b-mercaptoethanol (Sigma-Aldrich, St Louis, MO, USA).
Proteins were electrophoretically separated on pre-cast 10% SDS-polyacrylamide gels (Bio-Rad Laboratories Life Science Group, Hercules, CA, USA) and transferred to nitrocellulose. Rep proteins were detected by application of an anti-rep antibody (ARP American Research Product Inc., Belmont, MA, USA, catalog no. 03-61071) at 1:2000 followed by a goat anti-mouse HRP-conjugated secondary antibody (Pierce, catalog no. 31430) at 1:3000, and detected with SuperSignal West Pico Chemiluminescent Substrate and Enhancer (Pierce).
rHSV co-infection production of rAAV and purification for animal studies Mammalian cells were seeded into T75 flasks or cell factories and cell population was estimated at the time of infection (12-24 hps) by harvesting a T75 flask. Cells were co-infected with rHSV vectors at the indicated intervals. Infected cells were harvested post-infection at the indicated intervals by gentle pipetting (flasks) or manual agitation (cell factory).
Small-scale rAAV production and optimization experiments in (1 Â 10 7 cells) T75 flasks were processed by centrifugation (10 min, 4 1C, 1100 g), and resuspended in lysis buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% (w/v) DOC). Crude rAAV/GOI lysate was generated by three freeze-thaw cycles (À80 to 37 1C) and clarified by centrifugation (10 min, 4 1C, 2600 g). Clarified lysate was assayed as indicated.
Large-scale rAAV productions on HEK293 cells were executed in cell factories (1.0 Â 10 9 cells per CF) and harvested by in situ detergent lysis. Initial downstream processing consisted of Benzonase exposure (50 U ml À1 , 2 h, 37 1C) followed by clarification by depth filtration (0.5 mm)/dead-end filtration (0.5 mm), concentration by tangential flow filtration, and buffer exchange by diafiltration using a hollow fiber 300 kDa MWCO cartridge (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA, catalog no. UFP-300-C-9A). The three-column purification scheme for rAAV1/AAT consisted of mixed mode ion exchange (20 ml), anion exchange (5 ml) and gel filtration (30 ml) chromatography media, and was executed at a 1 Â 10 9 cell load on the first column. rAAV9/AAT was purified by double iodixanol gradient centrifugation. 60 Vector stocks used in animal studies were concentrated and buffer exchanged into lactated ringer's solution post-column chromatography using a 300 kDa MWCO hollow fiber cartridge (GE Lifesciences, catalog no. UFP-300-E-MM01A) for tangential flow filtration and diafiltration.
Animal experiments
Animal studies were approved by the University of Florida Institutional Animal Care and Use Committee (IACUC). Male C57BL/6 mice (6-8 weeks of age) were obtained from Charles River Laboratory. Mice were anesthetized by isoflurane inhalation, and purified rAAV vector preparations were injected into the quadriceps of both the hindlimbs using insulin syringes with 30G needles. Animals were injected with a total of 1.0 Â 10 10 or 1.0 Â 10 11 DRP in 100 ml of lactated ringer's solution. Blood was collected from mice at the indicated intervals by cheek bleeds. Blood samples were allowed to clot for 20 min at room temperature and then centrifuged at 10 000 g for 10 min. Sera were collected and stored at À80 1C.
ELISA for hAAT
Human a-1-antitrypsin standards (Athens Research and Technology, Athens, GA, USA) and mouse sera were serially diluted and incubated on MaxiSorp 96-well plates (Nunc-Immuno) coated with a goat anti-hAAT antibody (1:500, MP Biomedicals Inc., Solon, OH, USA) in Vollers buffer and blocked with 1 Â phosphatebuffered saline-Tween 20 containing 1% non-fat milk. hAAT was hybridized with a HRP-conjugated goat alpha1-AAT antibody (1:5000, Abcam Inc., Cambridge, MA, USA), reacted with tetramethyl benzidine substrate (Sigma-Aldrich) according to the manufacturer's instructions, quenched with 10% H 2 SO 4 and detected by reading absorbance 450 nm. Pooled human serum (Innovative Research, Novi, MI, USA) was used as the hAAT positive control quantified as l.5 mg ml À1 of a-1-antitrypsin.
